An Adult With Agenesis of Splenium of Corpus Callosum: A Case Report

Subhash Chander 1, Shahab Jazayeri 1, Julia Moulton 2, Shawnette Alston 1

1. Internal Medicine, Saint Mary’s Hospital, Waterbury, USA 2. Internal Medicine, Frank H. Netter MD School of Medicine, North Haven, USA

Corresponding author: Subhash Chander, subhash.lumhs@gmail.com

Abstract

A 22-year-old Hispanic immigrant presented to the emergency department after having a witnessed seizure. The patient was born and raised in Columbia and had a history of ventricular septal defect repair at the age of five years. Computer tomography (CT) of brain showed an unusual demonstration “heterotopia of gray matter” and the follow-up magnetic resonance imaging (MRI) revealed absence of splenium part of corpus callosum. The patient received a loading dose of IV antiepileptic medications and was then transitioned to oral dose. He was then discharged with seizure prophylaxis and referred for a follow-up at another tertiary care hospital for further workup. This case led to a management dilemma as the role of seizure prophylaxis in genetic brain malformations is not well established.

Introduction

History of seizures is as old as human existence. Initially, seizures were considered a divine malady or a hellish possession and diagnosed as a condition stemming from the hand of sin and brought by the god of the moon [1]. The first seizure patient was a male from the Mesopotamia region and was described as neck turning, hand and feet tensing up, eyes staying wide open and frothing from mouth while person lay unconscious.

Agenesis of the corpus callosum is a developmental abnormality that can occur as partial or complete absence of corpus callosum. Majority of the time, it presents with an isolated finding; however, it can appear in concurrence with other development or congenital disorders. Males have a higher incidence of neurodevelopmental abnormalities than females, and most anomalies reported are due to cerebellar hypoplasia, short gut syndrome, congenital nephrosis, and frontonasal dysplasia; however, these patients also reported severe intellectual disability as well [2].

Different age groups also have different risk factors. Additional risk factors such as infections, tumors, head trauma, and metabolic derangements can occur at any age. However, cerebrovascular disease and end organ failure complications, which also increase the risk of seizure, are mostly associated with older age. Most adulthood cases present with underlying brain development malformation.

Among all developmental malformations, agenesis of the corpus callosum (ACC) remains unobtrusive developmental defect. Of the 30–45% of cases with ACC with identifiable genetic causes, 20–35% are caused by a mutation affecting a single gene [3]. Several causative gene mutations have been identified in ACC [4]. Autosomal dominant, autosomal recessive, and X-linked inheritance have been recognized in several syndromes associated with ACC [5,6]. Large number of human genetic syndrome is associated with the agenesis of the corpus callosum.

Patient with complete agenesis presents with developmental delays, speech problems, and difficulties with social interactions. Majority of these cases present early in their life. Minor defects remain unreported and sometimes notified in their second and third decade of life. Patient with early presentation of seizure also has higher chance of conversion to epilepsy after experiencing at least two seizures within 24 hours. Also, studies have reported three times higher risk of death in comparison to those without epilepsy [7].

Case Presentation

A 22-year-old Hispanic male who, at the age of five years, moved to the United States was brought to emergency department (ED) by the emergency medical services after having a seizure at work, witnessed by his coworkers. The patient works in an information technology management company, and while talking on the phone, he complained of weakness and an uneasy feeling in his extremities. The patient also endorsed feeling dizzy, being lightheaded, having blurry vision, and had aura before the seizure. His coworker who witnessed the event described the patient as very rigid followed by generalized jerking of his body for
approximately 2 minutes before passing out. After waking up, he was confused for several minutes.

The patient is a healthy young adult, plays sports, and denies a previous history of seizures and substance use. He drinks alcohol occasionally; he last consumed it eight months prior to presenting in the ED. The patient’s past medical history was significant for ventricular septal defect which required surgical repair at the age of five years.

In ED, the patient was found to be hypertensive 143/48 mm Hg, tachycardic with heart rate of 111, and tachypneic. He was afebrile and maintained his O$_2$ saturation on room air. The patient was awake, active, and alert. All physical examinations were negative for any pertinent findings. Emergent seizure precautions were taken, and a CT scan without contrast was obtained. The patient was given a loading dose of IV levetiracetam for seizure.

Laboratory investigation at the time of presentation is illustrated in Tables 1, 2. CT scan of the brain revealed a heterotopic gray matter lesion on the left ventricle. For further characterization, magnetic resonance imaging (MRI) was performed which showed heterotopic gray matter along the periventricular aspect of the temporal and occipital lobes bilaterally (Figures 1A-1F). Neurology was consulted and the patient was admitted to the telemetry floor.

| Test Name                  | Results         | Normal Range   |
|----------------------------|-----------------|----------------|
| White blood cell count     | 6.2 × 10$^9$/L  | 4.5-11 × 10$^9$/L |
| Absolute neutrophil count | 3.3 × 10$^9$/L  | 1.8-7.7 × 10$^9$/L |
| Hemoglobin                 | 15.5 g/L        | 13.5-18.0 g/dL  |
| Platelet count             | 290 k/μL        | 150-200 k/μL    |
| Serum creatinine           | 0.9 mg/dL       | 0.7-1.2 mg/dL   |
| Serum sodium               | 133 mmol/L      | 135-145 mmol/L  |
| Serum potassium            | 3.6 mmol/L      | 3.5-5.1 mmol/L  |
| Serum urea nitrogen        | 20 mg/dL        | 8-21 mg/dL     |
| Estimated glomerular filtration rate | >60 mL/min/1.73 | >60 mL/min/1.73 |
| Serum bicarbonate          | 25 mmol/L       | 22-32 mmol/L    |
| Serum total calcium        | 9.2 mg/mL       | 8.4-10.3 mg/mL  |
| Serum ionized calcium      | 4.7 mg/mL       | 4.26-4.6 mg/mL  |
| Aspartate aminotransferase | 21 IU/L         | 13-36 IU/L      |
| Alanine aminotransferase   | 28 IU/L         | 6-40 IU/L       |
| Alkaline phosphatase       | 66 IU/L         | 45-115 IU/L     |
| Total bilirubin            | 0.6 mg/dL       | 0-1.2 mg/dL     |
| Magnesium                  | 2.1 mg/dL       | 1.9-2.7 mg/dL   |
| Phosphate                  | 3.5             | 2.5-5.0 mg/dL   |
| Blood cultures (2 sets)    | No growth after 5 days | N/A |

**TABLE 1: Laboratory investigations at the time of presentation**
| Test Name                    | Results | Normal Ranges                  |
|-----------------------------|---------|--------------------------------|
| Cortisol                    | 13.3 ug/dL | 6.7-22.6 ug/dL (AM) <10 ug/dL (PM) |
| TSH                          | 0.46 uU/mL | 0.45-5.33 uU/mL               |
| CK                           | 134     | 30-223 uU/mL                   |
| Lactic acid                 | 1.0 mmol/L | 0.5-2.0 mmol/L                |
| High sensitivity troponins  | 12      | 0-20 ng/L                      |
| Ethanol level               | ND      | ND                             |
| POC glucose                 | 114     | N/A                            |
| Creatinine                  | 0.9     | 0.48-1.10                      |
| Urine drug screen           |         |                                |
| Amphetamines                | Negative | Negative                       |
| Barbiturates                | Negative | Negative                       |
| Cocaine                     | Negative | Negative                       |
| Opiates                     | Negative | Negative                       |
| Oxycodeone                  | Negative | Negative                       |
| Benzodiazepine              | Negative | Negative                       |
| Phencyclidine               | Negative | Negative                       |
| Cannabinoids                | Negative | Negative                       |

**TABLE 2: Additional laboratory investigations (immunology/serology)**

TSH: thyroid-stimulating hormone; CK: creatine kinase; POC: point-of-care
The patient did not have any seizures on the subsequent day. His diet was advanced, and antiseizure medication was continued. Follow-up EEG reported no seizure-like activity and no further workup was suggested by neurology. After 24 hours, the patient was discharged on oral levetiracetam prophylaxis and referred to a nearby tertiary care hospital for follow-up genetic testing. It was recommended to the patient to avoid driving for at least three months as per state law.

**Discussion**

Seizure is the first clinical manifestation in up to two third of corpus callosum malformation. A patient with agenesis of the corpus callosum may have been admitted with other congenital abnormalities like ventricular septal defect, renal agenesis, and neurological disorders before the possibility of ACC is raised [7]. Many studies have reported higher risk of recurrent in children with congenital defects as compared to idiopathic causes and non-morphological defects [8,9].
Approximately 80% of the world’s people with epilepsy live in low to middle-income countries and most of the cases remain undiagnosed due to lack of healthcare resources, education, and parents’ awareness [10]. Cultural beliefs, traditional practices, and social relationships play a vital role in daily life of majority of people in developing countries. More importantly, immigrants to western countries do not generally dissociate themselves from previously held ethnomedical beliefs about health, sickness, and care [11].

People with newly diagnosed seizure and neurological deficits present since birth including mental retardation or cerebral palsy reported the highest mortality. However, patients with epilepsy have up to threefold increase in mortality as compared to general population [12].

Genetic testing also helps guide the associated therapeutic options. In addition, genetic testing is often necessary for infants and young children with congenital defects with epilepsy syndrome. However, it should also be considered in older patients with a history suggesting an undiagnosed genetic epilepsy syndrome that began early in life. Recent studies have shown the effect of genetic mutation may cause both epilepsy and a cardiac conduction defect that gives rise to sudden death (Table 3) [13,14].

| Syndrome                  | Chromosomal Region | Gene   |
|---------------------------|--------------------|--------|
| Autosomal-dominant        |                    |        |
| Apert syndrome            | 10q26              | FGFR2  |
| Basal cell nevus syndrome | 9q22.3             | PTCH   |
| Miller-Dieker syndrome    | 17q13.3            | LIS1   |
| Rubinstein-Taybi syndrome | 16p13.3            | CREBBP |
| Autosomal recessive       |                    |        |
| Andermann syndrome        | 15q13-q14          | SLC12A6|
| Acrorcallosal syndrome    | 7q13               | GLI3   |
| Joubert syndrome          | 6q23.2-q23.3       | AHI1   |
| Muscle-eye-brain disease  | 1q34-p33           | POMGNT1|
| X-linked                  |                    |        |
| ATR-X syndrome            | Xq13               | ATRX   |
| Craniofrontonasal syndrome| Xq12               | EFNB1  |
| Optiz G/BBB syndrome      | Xq22               | MID1   |
| Proud syndrome            | Xp22.13            | ARX    |

**TABLE 3: Genetic syndromes with agenesis of the corpus callosum (ACC)**

Adulst with single unprovoked first seizure and having prior brain insult and significant brain imaging abnormality have an increased risk of recurrence in the first two years [15]. Immediate anti-epileptic drugs (AEDs) therapy after first seizure may reduce the risk of second seizure in two years; however, it may not improve the quality of life. Longer treatment >5 years unlikely improves the prognosis for seizure remission [15-17].

**Conclusions**

In our patient, the very first unprovoked seizure episode not only created a dilemma of living with this disease but also opened a wide discussion about the recurrence of seizures and future consequences of unknown other organ diseases. Better knowledge of his genetic makeup and treatment options will not only prevent future seizure episodes but also bridge the gap between favorable and unfavorable outcomes of the disease itself.

**Additional Information**

**Disclosures**

*Human subjects:* Consent was obtained or waived by all participants in this study. *Conflicts of interest:* In
Compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Magiorkinis E, Sidiropoulou K, Diamantis A: Hallmarks in the history of epilepsy: epilepsy in antiquity. Epilepsy Behav. 2010, 17:103-8. 10.1016/j.yebeh.2009.10.023
2. Dobyns WB, Guerini R, Czaplansky-Beilman DK, et al.: Bilateral periventricular nodular heterotopia with mental retardation and syndactyly in boys: a new X-linked mental retardation syndrome. Neurology. 1997, 49:1042-7. 10.1212/WNL.49.4.1042
3. Bedeschi MF, Bonaglia MC, Grasso R, et al.: Agenesis of the corpus callosum: clinical and genetic study in 63 young patients. Pediatr Neurol. 2006, 34:186-93. 10.1016/j.pediatrneurol.2005.08.008
4. Schell-Apacik CC, Wagner K, Bihler M, et al.: Agenesis and dysgenesis of the corpus callosum: clinical, genetic and neuroimaging findings in a series of 41 patients. Am J Med Genet A. 2008, 146A:2501-11. 10.1002/ajmg.a.32476
5. Dobyns WB: Absence makes the search grow longer. Am J Hum Genet. 1996, 58:7-16.
6. Paul LK, Brown WS, Adolphs R, Tyszka JM, Richards LJ, Mukherjee P, Sherr EH: Agenesis of the corpus callosum: genetic, developmental and functional aspects of connectivity. Nat Rev Neurosci. 2007, 8:287-99. 10.1038/nrn2107
7. Stoll C, Dott B, Roth MP: Associated anomalies in cases with agenesis of the corpus callosum. Am J Med Genet A. 2019, 179:2101-11. 10.1002/ajmg.a.6359
8. Auer SP, Bialer M, Bougeret AM, et al.: Risk of recurrence after a first unprovoked seizure. Epilepsia. 2008, 49:1042-7. 10.1111/j.1528-1157.2008.tb00549.x
9. Hauser WA, Anderson VE, Loewenson RB, McRoberts SM: Seizure recurrence after a first unprovoked seizure. N Engl J Med. 1982, 307:522-8. 10.1056/NEJM198208263070905
10. Feigin VL, Nichols E, Alam T, et al.: Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019, 18:459-80. 10.1016/S1474-4422(19)30499-X
11. Ibenene S, Eni G, Emena A, Fortwengel G: Roads to health in developing countries: understanding the intersection of culture and healing. Curr Ther Res Clin Exp. 2017, 86:13-8. 10.1016/j.curtheres.2017.03.001
12. Lindsten H, Nyström L, Forsgren L: Mortality risk in an adult cohort with a newly diagnosed unprovoked epileptic seizure: a population-based study. Epilepsia. 2000, 41:1469-73. 10.1111/j.1528-1157.2000.tb00549.x
13. Barkovich AJ, Kuzniecky RI: Gray matter heterotopia. Neurology. 2000, 55:1605-8. 10.1212/wnl.55.11.1605
14. Asadollahi R, Zweier M, Gogoll L, Schiffmann R, Sticht H, Steinidi K, Rauch A: Genotype-phenotype evaluation of MED13L defects in the light of a novel truncating and a recurrent missense mutation. Eur J Med Genet. 2017, 60:451-64. 10.1016/j.ejmg.2017.06.004
15. Hopkins A, Garman A, Clarke C: The first seizure in adult life. Value of clinical features, electroencephalography, and computerised tomographic scanning in prediction of seizure recurrence. Lancet. 1988, 1:721-6. 10.1016/s0140-6736(88)9148-8
16. Marson A, Jacoby A, Johnson A, Kim L, Gamble C, Chadwick D: Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005, 365:2007-13. 10.1016/s0140-6736(05)66914-9
17. Gloss D, Pargeon K, Pack A, et al.: Antiseizure medication withdrawal in seizure-free patients: practice advisory update summary: report of the AAN guideline subcommittee. Neurology. 2021, 97:1072-81. 10.1212/WNL.0000000000012944